Market closed
4D Molecular Therapeutics/FDMT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About 4D Molecular Therapeutics
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.
Ticker
FDMT
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
201
FDMT Metrics
BasicAdvanced
$427M
Market cap
-
P/E ratio
-$2.32
EPS
2.82
Beta
-
Dividend rate
Price and volume
Market cap
$427M
Beta
2.82
52-week high
$36.25
52-week low
$7.90
Average daily volume
1.1M
Financial strength
Current ratio
28.482
Quick ratio
27.931
Long term debt to equity
1.778
Total debt to equity
2.321
Management effectiveness
Return on assets (TTM)
-16.86%
Return on equity (TTM)
-24.06%
Valuation
Price to revenue (TTM)
19.263
Price to book
0.72
Price to tangible book (TTM)
0.72
Price to free cash flow (TTM)
-4.468
Growth
Revenue change (TTM)
784.81%
Earnings per share change (TTM)
-29.01%
3-year revenue growth (CAGR)
-4.24%
3-year earnings per share growth (CAGR)
-8.65%
What the Analysts think about FDMT
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for 4D Molecular Therapeutics stock.
FDMT Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
FDMT Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
FDMT News
AllArticlesVideos
4D Molecular Therapeutics Inc Is Being Investigated For Securities Fraud And The Schall Law Firm Urges Affected Investors To Reach Out
Accesswire·8 hours ago
4D Molecular Therapeutics Inc Is Being Investigated For Securities Fraud And The Schall Law Firm Urges Affected Investors To Take Part
Accesswire·6 days ago
Shareholders Are Invited To Join The Schall Law Firm In An Inquiry Into 4D Molecular Therapeutics, Inc. For Securities Law Violations
Accesswire·1 week ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for 4D Molecular Therapeutics stock?
4D Molecular Therapeutics (FDMT) has a market cap of $427M as of October 26, 2024.
What is the P/E ratio for 4D Molecular Therapeutics stock?
The price to earnings (P/E) ratio for 4D Molecular Therapeutics (FDMT) stock is 0 as of October 26, 2024.
Does 4D Molecular Therapeutics stock pay dividends?
No, 4D Molecular Therapeutics (FDMT) stock does not pay dividends to its shareholders as of October 26, 2024.
When is the next 4D Molecular Therapeutics dividend payment date?
4D Molecular Therapeutics (FDMT) stock does not pay dividends to its shareholders.
What is the beta indicator for 4D Molecular Therapeutics?
4D Molecular Therapeutics (FDMT) has a beta rating of 2.82. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.